EARNINGS (LOSS) PER SHARE

9 Months Ended

Mar. 31, 2021

The following table sets forth the computation of basic and diluted net income (loss) per share:


	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Numerator:
Net income from continuing operations	$	34,254	$	25,036	$	25,624	$	21,935
Net (loss) income from discontinued operations	—		(697)		11,255		(105,581)
Net income (loss)	$	34,254	$	24,339	$	36,879	$	(83,646)

Denominator:
Basic weighted average shares outstanding	99,831		104,032		100,502		104,192
Effect of dilutive stock options, unvested restricted stock and unvested restricted share units	1,765		305		883		297
Diluted weighted average shares outstanding	101,596		104,337		101,385		104,489

Basic net income (loss) per common share:
Continuing operations	$	0.34	$	0.24	$	0.25	$	0.21
Discontinued operations	—		(0.01)		0.11		(1.01)
Basic net income (loss) per common share	$	0.34	$	0.23	$	0.36	$	(0.80)

Diluted net income (loss) per common share:
Continuing operations	$	0.34	$	0.24	$	0.25	$	0.21
Discontinued operations	—		(0.01)		0.11		(1.01)
Diluted net income (loss) per common share	$	0.34	$	0.23	$	0.36	$	(0.80)

Basic net income (loss) per share excludes the dilutive effects of stock options, unvested restricted stock and unvested restricted share units.

There were 4 and 512 restricted stock awards and stock options excluded from our calculation of diluted net income per share for the three months ended March 31, 2021 and 2020, respectively, as such awards were anti-dilutive. Additionally, there were 23 and 2,616 stock-based awards excluded for the three months ended March 31, 2021 and 2020, respectively, as such awards were contingently issuable based on market or performance conditions, and such conditions had not been achieved during the respective periods.

There were 182 and 450 restricted stock awards and stock options excluded from the calculation of diluted net income (loss) per share for the nine months ended March 31, 2021 and March 31, 2020, respectively, as such awards were anti-dilutive. Additionally, there were 957 and 2,685 stock-based awards excluded for the nine months ended March 31, 2021 and 2020, respectively, as such awards were contingently issuable based on market or performance conditions, and such conditions had not been achieved during the respective periods.

Share Repurchase Program

On June 21, 2017, the Company's Board of Directors authorized the repurchase of up to $250,000 of the Company’s issued and outstanding common stock. Repurchases may be made from time to time in the open market, pursuant to pre-set trading plans, in private transactions or otherwise. The authorization does not have a stated expiration date. The extent to which the Company repurchases its shares and the timing of such repurchases will depend upon market conditions and other corporate considerations. During the three months ended March 31, 2021, the Company repurchased 204 shares under the repurchase program for a total of $8,562, excluding commissions, at an average price of $41.86 per share. During the nine months ended March 31, 2021, the Company repurchased 2,408 shares under the repurchase program for a total of $80,255, excluding commissions, at an average price of $33.33 per share. As of March 31, 2021, the Company had $109,495 of remaining authorization under the share repurchase program.